This marks Enzene’s sixth biosimilar in the Indian market and highlights Enzene’s commitment to providing accessible healthcare solutions. Manufactured using Enzene Biosciences’ patented Continuous Manufacturing Process, Bevacizumab is a biosimilar to Avastin® and will be available through a non-exclusive partnership for pharmaceutical firms in India
Pune, 29th June 2023: Known for its disruptive innovation and extensive experience in developing high-quality biosimilars, Pune-based Enzene Biosciences has now announced the India launch of Bevacizumab, a biosimilar of Avastin® that is used for the treatment of metastatic colorectal cancer. An alternative to the more expensive Avastin® biologic, Bevacizumab is the 6th biosimilar from Enzene Biosciences’ strong biosimilar pipeline that has been launched in the Indian market. Aimed at penetrating the Indian market for Bevacizumab that is valued at ~₹260 crores, Enzene’s version is the first of its kind to be manufactured using the firm’s patented continuous manufacturing process at its Pune facility.
“Enzene Biosciences is at the forefront of providing affordable healthcare solutions during this critical time,” stated Dr. Himanshu Gadgil, CEO of Enzene Biosciences Ltd. “With our commitment to incorporating the latest technologies in drug manufacturing, we have successfully developed the Bevacizumab biosimilar our 6th Biosimilar product for Indian patients. Utilizing our fully integrated and automated continuous biologics manufacturing process, we uphold stringent quality standards while reducing overall manufacturing costs. We are confident that the significant price reductions passed on by our partners will greatly benefit thousands of metastatic colorectal cancer patients, supporting our mission to make cancer treatment more accessible and affordable in our country.”
Also used in the treatment of non-squamous non-small cell lung cancer and glioblastoma, Enzene’s Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that is effective against vascular endothelial growth factor called VEGF. Bevacizumab acts by binding to VEGF and subsequently inhibiting its receptor binding process, thereby preventing the growth of the tumor and cancerous cells in affected patients. Considered the sixth most common form of cancer in India, colorectal cancer patients in the country will be the ultimate benefactors as Enzene’s Bevacizumab will be supplied at a radically lower cost to the company’s B2B partners such as Alkem Laboratories and other big pharma players. Moreover, with its significantly smaller production facility and lower carbon emissions, Enzene Biosciences is also addressing the current need for more ecologically sustainable manufacturing operations.
“Enzene Biosciences is poised to revolutionize the landscape of biosimilar manufacturing,” stated Sandeep Singh, MD of Alkem Laboratories. “Our remarkable progress in developing a Bevacizumab biosimilar exemplifies our commitment to making a lasting impact on human lives through manufacturing innovation. By strategically investing in state-of-the-art technologies, we have successfully disrupted the cost of producing biosimilar monoclonal antibodies, propelling us closer to our ultimate vision of delivering affordable healthcare to individuals affected by debilitating illnesses. With an unwavering dedication, we are steadfast in our mission to emerge as the forefront biotech company in the nation, positively shaping the global healthcare ecosystem through trusted and accessible biosimilar solutions.“
With the launch of Bevacizumab, Enzene Biosciences has now successfully introduced biosimilars for the treatment of critical illnesses such as squamous cell cancer of the head and neck, osteoporosis, postmenopausal osteoporosis, immune thrombocytopenic purpura (ITP), rheumatoid arthritis and metastatic colorectal cancer. The company has multiple biosimilars and synthetic peptides that are in the development and clinical stage, for the delay of imminent pre-term birth and the treatment of Type II diabetes mellitus, chronic idiopathic constipation and osteoporosis. A subsidiary of Alkem Laboratories, the company is emerging as a key player in the domestic biosimilar market and the global CDMO space, and is securing India’s position as an innovative manufacturing hub that is catering to the world’s healthcare needs.
About Enzene Biosciences Ltd:
Enzene is an innovation-driven biotech company a subsidiary of Alkem Laboratories Ltd. (one of the top five pharmaceutical companies in India) located in Pune, India. Enzene’s focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services with capabilities from clone development up to GMP manufacturing supported by bioreactor capacities ranging from 20 litres to 2000 litres.
About Alkem Laboratories Limited:
Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA data March 2022). The company also has presence in more than 40 international markets, with the United States being its key focus market.
Media Contacts:
Veritas Reputation PR | Veritas Reputation PR |
Sapana. Y
9660102344 |
Abhishek Savant 8108848822 abhishek@veritasreputation.com |
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.